Peregrine's Licensee Initiates Phase I Clinical Trial In Europe With Novel Tumor Necrosis Therapy Cancer Agent

Fri, 23 Feb 2007 02:00 PM EST

... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that one of its licensees has initiated European clinical trials of a novel anti-cancer agent developed with technology licensed from Peregrine. [click link for full article] ...